rs179247 — TSHR TSHR Intron 1 Graves' Disease Risk Variant

Intronic regulatory variant in TSHR intron 1; the A allele reduces thymic expression of the TSH receptor, impairing central tolerance to thyroid antigens and increasing susceptibility to Graves' disease — the most common autoimmune cause of hyperthyroidism

See your personal result for TSHR

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TSHR Intron 1 rs179247 — The Original Graves' Susceptibility Signal

When researchers set out to systematically fine-map the thyroid stimulating hormone receptor gene for Graves' disease susceptibility, rs179247 was the variant that emerged most strongly. In the landmark 2009 discovery study by Brand et al. in Human Molecular Genetics11 Brand et al. in Human Molecular Genetics
Systematic SNP analysis across 800 kb spanning TSHR in 768 GD cases and 768 matched controls, European descent, rs179247 produced the single strongest statistical signal across the entire TSHR locus — a chi-square of 32.45, odds ratio of 1.53, and p-value of 8.9×10⁻⁸. Subsequent conditional analyses found that rs12101255, located ~18 kb downstream in the same intron 1 haplotype block, is the stronger independent driver, but rs179247 and rs12101255 together form the canonical TSHR intron 1 risk haplotype. Carrying both A (rs179247) and T (rs12101255) risk alleles amplifies susceptibility beyond either alone.

The Mechanism

TSHR intron 1 contains a regulatory element that governs tissue-restricted expression of the TSH receptor — particularly in the thymus, where developing T cells are trained to recognise and delete self-reactive clones. This [central tolerance checkpoint | The thymus eliminates T cells that react to the body's own antigens; gaps in this deletion process leave autoreactive T cells free to circulate and, under trigger conditions, launch an autoimmune attack] relies on thymic epithelial cells presenting TSHR fragments to immature T cells. When TSHR expression in thymic cells is insufficient, autoreactive T cells that would normally be destroyed can escape into the periphery.

rs179247 sits within this intron 1 regulatory region and tags a haplotype block that influences full-length TSHR mRNA expression. In the Brand 2009 study, the AA risk genotype correlated with reduced ratios of full-length TSHR mRNA relative to two alternate splice variants in thyroid tissue — the same functional pattern documented for the companion rs12101255 risk genotype. Reduced full-length TSHR transcript in thymic epithelial cells weakens the tolerance-training signal, leaving room for TSHR-reactive T cells to survive and eventually drive the autoimmune cascade of Graves' disease.

The Evidence

rs179247 was first identified in 2009 by Brand et al.22 Brand et al.
768 GD cases and 768 controls; systematic coverage of TSHR with 97 tagging SNPs across 800 kb as the strongest association in the TSHR locus (OR 1.53, P=8.9×10⁻⁸), with replication in 303 GD families. Płoski et al.33 Płoski et al.
Warsaw, Gliwice, and UK cohorts including up to 2,504 patients and 2,784 controls (2010) confirmed OR 1.38–1.45 (P from 1.2×10⁻² to 6.2×10⁻¹⁵) across three European cohorts, though conditional regression placed the primary causal signal at rs12101255.

Two independent 2016 meta-analyses quantified the risk comprehensively. The Gong et al. meta-analysis44 Gong et al. meta-analysis
Seven studies, 5,754 GD cases, 5,768 controls; pooled across Asian and European populations reported: A vs G allele OR 1.40 (95% CI 1.33–1.48); AA vs GG OR 1.94 (95% CI 1.73–2.19); dominant model (AA+AG vs GG) OR 1.57 (95% CI 1.41–1.74). The Qian et al. meta-analysis55 Qian et al. meta-analysis
Cross-ethnic pooled analysis including Asian, European, and South American cohorts reported a pooled allele OR of 1.422 (95% CI 1.353–1.495, P<0.001) with negligible heterogeneity (P_het=0.448) — an unusually consistent signal across ethnic backgrounds.

The Xiong et al. meta-analysis66 Xiong et al. meta-analysis
4,790 cases, 5,350 controls, 8 studies covering rs179247, rs12101255, and rs2268458 (2016) confirmed association in all genetic models and noted no differential effect on Graves' ophthalmopathy versus Graves' disease without orbital involvement. A Chinese Han study by Liu et al.77 Liu et al.
404 GD, 230 Hashimoto's thyroiditis, 242 controls (2012) further showed the rs179247-rs12101255 AT haplotype carried higher risk (OR=1.368) than rs12101255 alone, and found that the rs179247 A allele specifically associated with Graves' ophthalmopathy severity within GD patients.

Practical Actions

The A allele at rs179247 is common — approximately 49% of Europeans and 64% of East Asians carry it — making it a population-level susceptibility variant rather than a rare pathogenic mutation. AA homozygotes face roughly 1.94-fold elevated odds of Graves' disease compared with GG carriers. The priority is early recognition of hyperthyroid symptoms, awareness of precipitating triggers (particularly viral illness, excess iodine, and postpartum immune shifts), and baseline antibody testing to detect pre-clinical autoimmunity.

Selenium at 100–200 mcg/day reduces autoimmune thyroid antibody titres in RCTs and has specific evidence in Graves' patients for lowering TSH receptor antibody (TRAb) levels. Limiting unnecessary iodine supplementation is especially relevant for AA carriers given the elevated baseline risk.

Interactions

rs179247 and rs12101255 are the two best-studied SNPs in TSHR intron 1, located ~18 kb apart within the same haplotype block. Conditional regression in multiple European cohorts shows their signals overlap substantially — rs12101255 appears to be the stronger independent driver — but the AT haplotype (A at rs179247, T at rs12101255) confers higher risk than rs12101255 T alone in Chinese Han populations. Carrying risk alleles at both loci represents the maximum-risk TSHR intron 1 configuration.

Independent of TSHR, Graves' susceptibility is also shaped by HLA class II alleles (DRB1, DQA1), PTPN22 R620W (rs2476601), and CTLA4 variants (rs3087243, rs231775). These loci act through T-cell activation threshold mechanisms distinct from the thymic TSHR expression mechanism at this locus, and their effects on Graves' risk are additive.

Genotype Interpretations

What each possible genotype means for this variant.

GG Protective Genotype Normal

Protective G alleles — no TSHR intron 1 contribution to Graves' disease risk

You carry two copies of the G allele at rs179247 — the lower-risk genotype at this TSHR intron 1 locus. Approximately 16% of people globally share this genotype (more common in South Asians at ~35%, less common in Africans at ~4%). The GG configuration is associated with higher full-length TSHR mRNA expression in thymic epithelial cells, supporting intact central tolerance training against thyroid antigens at this locus. This does not eliminate Graves' disease risk — other genetic and environmental factors also contribute — but the rs179247 locus does not elevate your risk.

AG One Risk Allele Intermediate

One A risk allele — modestly elevated Graves' disease susceptibility

rs179247 follows a codominant pattern in which heterozygotes occupy an intermediate risk tier between GG (protective) and AA (highest risk). The A allele at rs179247 is in linkage disequilibrium with the T allele at rs12101255 (~18 kb downstream), and the two together form the canonical TSHR intron 1 risk haplotype. Your rs12101255 result will clarify whether you carry the full haplotype or only the rs179247 A allele in isolation.

Graves' disease affects roughly 1–2% of women and 0.1–0.2% of men over a lifetime. Environmental triggers with the clearest mechanistic link to TSHR intron 1 variants include viral infection (interferon-alpha suppresses thymic TSHR expression) and excess iodine (which precipitates autoimmune thyroid inflammation). Postpartum immune rebound is a well-established Graves' trigger independent of genotype.

AA Two Risk Alleles High Risk

Two A risk alleles — substantially elevated Graves' disease susceptibility (~1.94-fold vs GG)

The AA genotype at rs179247 sits at the top of the TSHR intron 1 risk tier. Both copies of the intron 1 regulatory region carry the A allele, maximising the reduction in thymic TSHR expression documented for this haplotype. This impairs the clonal deletion of TSHR-reactive T cells at both alleles simultaneously.

The separate Chinese Han haplotype analysis by Liu et al. 2012 found that the rs179247 A allele — beyond contributing to overall Graves' disease risk — specifically associated with Graves' ophthalmopathy (the eye manifestation affecting 25–30% of Graves' patients). Ophthalmopathy involves inflammatory expansion of orbital fibroblasts driven by TRAb binding to TSHR on orbital tissue; earlier Graves' diagnosis and rapid achievement of euthyroidism limits the cytokine environment that drives orbital involvement.

Graves' disease is a known risk factor for secondary complications: sustained thyrotoxicosis accelerates bone density loss (particularly in postmenopausal women) and can trigger atrial fibrillation. Both complications are substantially reduced by early diagnosis and treatment.

The A allele frequency varies dramatically by ancestry: ~81% in Africans versus ~49% in Europeans, meaning AA is far more prevalent in African-ancestry populations (~65%) than in European-ancestry populations (~24%). Population-specific absolute risk figures differ accordingly.